1. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies;Zhao;Clin. Infect. Dis.,2001
2. Mutation prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae;Blondeau;Antimicrob. Agents Chemother.,2001
3. Allen GP, Kaatz GW, Blondeau JM, Rybak MJ. Evaluation of the mutant prevention concentration (MPC) for fluoroquinolones against Streptococcus pneumoniae—effects on development of resistance in an in vitro pharmacodynamic model. In: Abstracts of the 22nd International Congress of Chemotherapy, Amsterdam, NL, June–July 2001. p. 73 [Abstract #27.107].
4. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model;Allen;Antimicrob. Agents Chemother.,2003
5. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus;Firsov;Antimicrob. Agents Chemother.,2003